SPRIM Global Investments
VC Fund
New York, United States
SPRIM Global Investments is a privately held investment company. SGI was established in 2008 following the global expansion of SPRIM Consulting & Services business.SPRIM Global Investments leverages the funnel of SPRIM’s sourcing, screening and selection processes across the globe to identify and invest in high potential health solutions. Wefind dynamic young companies proposing innovative offerings and help them to accelerate their growth. These startups can, in turn, leverage the SPRIM network, enabling them to fast-track their development. Our portfolio companies have full access to SPRIM’s fellow venture company experts across the globe as well as the company’s investment vehicles.
- Total investments:
- 19
- Last investment:
- Lead investor:
- 89%
Last updated:
For AI agents: llms.txt
Industries SPRIM Global Investments invests in
Stages SPRIM Global Investments invests in
Countries SPRIM Global Investments invests in
Round sizes
Round size
- Series A
- $10M–$22M
- Debt Financing
- $500k–$26M
Investment Focus
Industry
- Biotechnology 9 (47%)
- Health Care 6 (32%)
- Medical Device 4 (21%)
- Pharmaceutical 4 (21%)
- Therapeutics 3 (16%)
Stage
- Series A 5 (26%)
- Debt Financing 3 (16%)
- Venture - Series Unknown 2 (11%)
- Seed 1 (5%)
- Series B 1 (5%)
Country
- Australia 3 (16%)
- United States 3 (16%)
- France 2 (11%)
- Switzerland 2 (11%)
- Italy 1 (5%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Body Vision Medical
|
Body Vision Medical eliminates CT-to-body divergence and provides visual confirmation of tool-in-lesion prior to biopsy, while intraoperative CT imaging and enhanced fluoroscopy provide unparalleled control over diagnostic output. They can be a dedicated intraoperative 3D imaging solution for tool-in-lesion confirmation or a standalone navigationalbronchoscopy platform. | Venture - Series Unknown / Aug 06, 2026 | |
NinaMED
|
NinaMED is a healthcare and medical solutions company associated with medical services and technology-enabled healthcare solutions. | $10M / Seed / May 13, 2026 | |
ErVimmune
|
ErVimmune creates novel immunotherapies that target non-conventional tumor antigens that are abnormally expressed in cancer cells and shared by tumors and patients, with a particular emphasis on meeting unmet medical requirements in cold malignancies. | $19.9M / Series A / Jan 21, 2026 | |
KAHR medical
|
KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders. | $10M / Debt Financing / Oct 15, 2025 | |
Vaxxas
|
Vaxxas develops and commercializes needle-free vaccine delivery system. Vaxxas was incorporated in 2011 and is based in Brisbane, Australia. | $31.8M / Series D / Aug 25, 2025 | |
|
Vaxxas
|
Vaxxas develops and commercializes needle-free vaccine delivery system. Vaxxas was incorporated in 2011 and is based in Brisbane, Australia. | $25.9M / Debt Financing / Aug 25, 2025 | |
Azalea Vision
|
Azalea Vision is a medical manufacturer designing contact lenses with an active light management system for people with ocular disorders. | $10.3M / Series A / Apr 29, 2025 | |
RheumaGen
|
RheumaGen is a gene-editing technology developing therapeutics to cure rheumatoid arthritis. It offers an HLA gene-editing platform that uses stem-cell-enriched blood to alter DNA to suppress the immune system and stop rheumatoid arthritis's abnormal immune response. | $15M / Series A / Jan 09, 2025 | |
CILcare
|
CILcare specializes in providing drug solutions for hearing and ear disorders. | $42M / Series A / Dec 04, 2024 | |
Doron Therapeutics
|
Doron Therapeutics is a clinical-stage biotechnology company that has developed intra-articular biologic drugs derived from placental tissue and consistently delivers a host of beneficial growth factors with potent anti-inflammatory, tissue-protective, and regenerative capabilities pivotal to the progressive and degenerative disease ofosteoarthritis. | $11M / Series A / Nov 25, 2024 | |
| See all 19 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does SPRIM Global Investments invest in?
SPRIM Global Investments invests primarily in Biotechnology, Health Care and Medical Device startups, most often at Series A and Debt Financing stage. Most of the 19 investments tracked by Shizune back companies in Australia. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is SPRIM Global Investments's check size?
SPRIM Global Investments typically joins rounds of $10M–$22M at Series A and $500k–$26M at Debt Financing. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds SPRIM Global Investments participates in.
When did SPRIM Global Investments last invest?
The most recent investment recorded for SPRIM Global Investments closed in Aug 2026. Shizune tracks 19 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
